Novo Nordisk cuts Ozempic and Wegovy prices up to 48% in India

Novo Nordisk (NYSE: NVO) reduced prices of its diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% respectively in India, the company said Tuesday.

The Danish pharmaceutical company implemented the price cuts to compete with local drugmakers offering generic versions of the medications in the Indian market.

You May Also Be Interested In

• Prologis makes unsolicited bid for SEGRO, valued at £12.6 billion
• U.S. Physical Therapy (USPH) Reiterated at Market Outperform by Citizens
• argenx SE (ARGX) Reiterated at Market Outperform by Citizens: Ph3 Results on Track for Q3